Biogen has welcomed receiving the first positive reimbursement decision to come from the BeNeLuxA partnership, the coalition of European countries seeking to improve access to medicines by working together to secure joint pricing and reimbursement decisions, among other things. The company says that the process was collaborative and constructive, although not without its challenges thanks to differences in local laws.
Two BeNeLuxA partners, Belgium and the Netherlands, agreed to reimburse Biogen’s orphan drug Spinraza (nusinersen) following joint health technology assessment and pricing negotiations. This marks the first time the coalition has reached a positive joint reimbursement decision, although the other coalition partners – Ireland, Austria and Luxembourg – were this time not involved in the decision making
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?